CD4 and non-small cell lung carcinoma: For example, in NSCLC patients treated with ICIs, the number of CD4+CD25+CD127loFoxP3+ Treg cells significantly decreased compared with that at baseline in patients with pseudoprogression one week after treatment, whereas the number of these cells markedly increased in patients with hyperprogression.